Clinical trial · no report yet · Phase 3
C-SMART
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
- NCT04534725 ↗
- Completed
- Peter MacCallum Cancer Centre, Australia
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; C-SMART Study.
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Cancer; Covid19; Respiratory Viral Infection
- Interventions
- Interferon alfa; Selinexor; Lenzilumab
- Arms
- prophylaxis · Experimental
- Post-Exposure Prophylaxis · Experimental
- Moderate COVID-19 infection · Experimental
- Severe COVID-19 infection · Experimental
- Enrollment
- 441
- Primary outcomes
- Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)
- incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing
- incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .
- incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing
- incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records
- time to clinical improvement or discharge from hospital assessed using medical records
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Start
- Dec 17, 2020
- Primary completion
- Nov 28, 2022
- Results posted
- No
- Registry record
- NCT04534725 · updated Aug 24, 2023
Publications
linked from the registry- Yong MK, Thursky K, Crane M, Spelman T, Mahar RK, Simpson JA, Scott AM, Harrison SJ, Szer J, Pellegrini M, Lingaratnam S, Pang KC, Tennakoon S, Sim BZ, Blyth E, Gan HK, Quach H, McIntosh MP, Page H, Woolstencroft R, Slavin M. Interferon-alpha Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial. Clin Infect Dis. 2026 Feb 25;82(2):e208-e216. doi: 10.1093/cid/ciaf409. PubMed 40874769
- Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. PubMed 34473343